Xiangtian Yu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Xiangtian Yu has a total of 146 co-authors. Here are the top co-authors by number of shared publications:
- Tao Zeng
Guangzhou National Laboratory Guangzhou China
10 shared publications - Cheng Hu
State Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer, Department of Endocrinology and Metabolism, Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Clinical Centre for Diabetes, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
5 shared publications - Zhenlin Zhang
Department of Osteoporosis and Bone Disease, Shanghai Clinical Research Center of Bone Disease, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China
4 shared publications Li Shen
Clinical Research Center, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
3 shared publications- Luonan Chen
School of Mathematical Sciences and School of AI, Shanghai Jiao Tong University, Shanghai, China
3 shared publications Mingjuan Luo
Department of Endocrinology and Metabolism, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China
3 shared publications
Latest Publications
- Open Access
- 8 October 2026
- Published by S. Karger AG in Liver Cancer
Dietary cholesterol promotes MASLD-related hepatocellular carcinoma through mitochondrial dysfunction
Background and Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent disease that can progress to hepatocellular carcinoma (HCC). Excess dietary cholesterol is associated with MASLD-HCC, but its role in liver malignancy remains unclear. Here, we aimed to investigate the mechanism of how dietary cholesterol promotes MASLD-HCC. Methods: C57BL/6 mice were fed with high-cholesterol (HC) or low-cholesterol (LC) diet for 14 months. Mouse liver tissues were subjected to transcriptome, whole-exome, and methylation sequencing. Cholesterol-lowering atorvastatin was used for intervention experiment. Mitochondrial function was assessed in mouse liver tissues and human MASLD-HCC cell lines. Plasma samples from 88 hypercholesteremia patients and 88 healthy individuals were collected. Results: Liver tumors were observed in HC-fed mice, and mitochondrial dysfunction was identified as the key pathway in cholesterol-induced MASLD-HCC. In particular, impaired mitochondrial function and reduced mitochondrial membrane potential and integrity were observed in the liver of HC-fed mice. Pten was the central gene associated with mitochondrial dysfunction in cholesterol-induced MASLD-HCC. Cholesterol also dysregulated mitochondrial function and promoted proliferation of human MASLD-HCC cells, whereas the pro-proliferative effect of cholesterol was reversed after pharmacological restoration of mitochondrial function. Similarly, atorvastatin treatment could restore mitochondrial function and increase Pten expression in HC-fed mice, thereby inhibiting MASLD-HCC development. Mechanistically, mitochondrial dysfunction in MASLD-HCC was caused by hypermethylation of mitochondria-associated genes. Hypercholesterolemia patients exhibited features of mitochondrial dysfunction, compared to healthy controls. Conclusion: Dietary cholesterol promotes MASLD-HCC by inducing methylation-mediated mitochondrial dysfunction and PTEN loss. Restoring mitochondrial function and cholesterol-lowering drugs might serve as potential therapeutics for MASLD-HCC.
- 8 October 2026
- Published by S. Karger AG in Liver Cancer
Open AccessDietary cholesterol promotes MASLD-related hepatocellular carcinoma through mitochondrial dysfunction
Background and Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent disease that can progress to hepatocellular carcinoma (HCC). Excess dietary cholesterol is associated with MASLD-HCC, but its role in liver malignancy remains unclear. Here, we aimed to investigate the mechanism of how dietary cholesterol promotes MASLD-HCC. Methods: C57BL/6 mice were fed with high-cholesterol (HC) or low-cholesterol (LC) diet for 14 months. Mouse liver tissues were subjected to transcriptome, whole-exome, and methylation sequencing. Cholesterol-lowering atorvastatin was used for intervention experiment. Mitochondrial function was assessed in mouse liver tissues and human MASLD-HCC cell lines. Plasma samples from 88 hypercholesteremia patients and 88 healthy individuals were collected. Results: Liver tumors were observed in HC-fed mice, and mitochondrial dysfunction was identified as the key pathway in cholesterol-induced MASLD-HCC. In particular, impaired mitochondrial function and reduced mitochondrial membrane potential and integrity were observed in the liver of HC-fed mice. Pten was the central gene associated with mitochondrial dysfunction in cholesterol-induced MASLD-HCC. Cholesterol also dysregulated mitochondrial function and promoted proliferation of human MASLD-HCC cells, whereas the pro-proliferative effect of cholesterol was reversed after pharmacological restoration of mitochondrial function. Similarly, atorvastatin treatment could restore mitochondrial function and increase Pten expression in HC-fed mice, thereby inhibiting MASLD-HCC development. Mechanistically, mitochondrial dysfunction in MASLD-HCC was caused by hypermethylation of mitochondria-associated genes. Hypercholesterolemia patients exhibited features of mitochondrial dysfunction, compared to healthy controls. Conclusion: Dietary cholesterol promotes MASLD-HCC by inducing methylation-mediated mitochondrial dysfunction and PTEN loss. Restoring mitochondrial function and cholesterol-lowering drugs might serve as potential therapeutics for MASLD-HCC.
- Open Access
- 1 January 2026
- Published by Wiley in Journal of Diabetes Research
- Vol. 2026 (1)
Metabolites in Early‐Mid Pregnancy Mediate the Association Between Prepregnancy Body Mass Index and Risk of Gestational Diabetes Mellitus
Aims: The study is aimed at identifying the shared metabolites in early‐mid pregnancy associated with prepregnancy body mass index (pBMI) and subsequent gestational diabetes mellitus (GDM) risk and at exploring the mediating role of metabolites. Methods: One hundred pregnant women with GDM and 100 matched controls were enrolled in the study. Serum samples were collected in 10–20 weeks’ gestation and used for targeted metabolomic assay measurement. The associations among pBMI, metabolites, and GDM were investigated using linear regression and logistic regression models. Mediation analysis was conducted to evaluate the mediating effect of individual metabolite and clustered latent variable (LV) on the association of pBMI with GDM. Results: We identified eight metabolites significantly associated with both pBMI and GDM, which contained three organic acids, three acylcarnitines, and two fatty acids. Mediation analysis found five individual metabolites and two clustered LVs exhibited significant mediation effects in the association between pBMI and GDM risk. LV1 showed mediated proportions of 24.0%, which represented as organic acids and enriched in branched‐chain amino acid biosynthesis. LV2 showed mediated proportions of 19.1%, which represented as acylcarnitines and enriched in linoleic acid metabolism. Furthermore, we validated the mediating role of branched‐chain amino acids during the OGTT period. Conclusion: The association between pBMI and GDM risk was attributed to serum metabolites in early‐mid pregnancy, especially metabolites related to branched‐chain amino acid biosynthesis.
- 1 January 2026
- Published by Wiley in Journal of Diabetes Research
- Vol. 2026 (1)
Open AccessMetabolites in Early‐Mid Pregnancy Mediate the Association Between Prepregnancy Body Mass Index and Risk of Gestational Diabetes Mellitus
Aims: The study is aimed at identifying the shared metabolites in early‐mid pregnancy associated with prepregnancy body mass index (pBMI) and subsequent gestational diabetes mellitus (GDM) risk and at exploring the mediating role of metabolites. Methods: One hundred pregnant women with GDM and 100 matched controls were enrolled in the study. Serum samples were collected in 10–20 weeks’ gestation and used for targeted metabolomic assay measurement. The associations among pBMI, metabolites, and GDM were investigated using linear regression and logistic regression models. Mediation analysis was conducted to evaluate the mediating effect of individual metabolite and clustered latent variable (LV) on the association of pBMI with GDM. Results: We identified eight metabolites significantly associated with both pBMI and GDM, which contained three organic acids, three acylcarnitines, and two fatty acids. Mediation analysis found five individual metabolites and two clustered LVs exhibited significant mediation effects in the association between pBMI and GDM risk. LV1 showed mediated proportions of 24.0%, which represented as organic acids and enriched in branched‐chain amino acid biosynthesis. LV2 showed mediated proportions of 19.1%, which represented as acylcarnitines and enriched in linoleic acid metabolism. Furthermore, we validated the mediating role of branched‐chain amino acids during the OGTT period. Conclusion: The association between pBMI and GDM risk was attributed to serum metabolites in early‐mid pregnancy, especially metabolites related to branched‐chain amino acid biosynthesis.
- Open Access
Quantifying cellular malignancy by tumor micro‐environment measurement with multimodal fusion
- Open Access
- 31 July 2025
- Published by Wiley in Journal of Diabetes
- Vol. 17 (8) , e70118
Non‐Traditional Lipid Parameters and Risk of Adverse Pregnancy Outcomes in Gestational Diabetes Mellitus: Mediation by Maternal Metabolites
Aims: To examine the association between non‐traditional lipid parameters and adverse pregnancy outcomes (APOs) in women with gestational diabetes mellitus (GDM) and the mediating role of maternal serum metabolites during pregnancy.Materials and Methods: This prospective observational study enrolled 399 women with GDM. Multivariate logistic regression was used to examine the association between non‐traditional lipid parameters and APOs risk. Additionally, we assessed the mediating role of single and composite maternal serum metabolites during pregnancy using causal mediation analysis and high‐dimensional mediation analysis, respectively.Results: APOs were observed in 12.0% (N = 48) of participants. Seven non‐traditional lipid parameters, except for the RC/HDL‐C ratio, were associated with APOs risk, with the highest estimate for the atherogenic index of plasma (AIP) (OR = 3.873, 95% CI: 1.079–13.934, p = 0.037) after adjusting for confounders. Maternal metabolic markers mediated these associations, with mediation effect proportions of 21.9%–39.4%. Seven key metabolic markers were identified as potential mediators primarily involved in the biosynthesis of the unsaturated fatty acids pathway. Gene set variation analysis revealed significant differences in the positive regulation of this pathway between the APO and normal pregnancy outcome groups (p = 0.015).Conclusions: Non‐traditional lipid parameters were positively associated with APOs risk in women with GDM. Maternal serum metabolites, predominantly involved in the biosynthesis of unsaturated fatty acids, contribute to these associations.
- 31 July 2025
- Published by Wiley in Journal of Diabetes
- Vol. 17 (8) , e70118
Open AccessNon‐Traditional Lipid Parameters and Risk of Adverse Pregnancy Outcomes in Gestational Diabetes Mellitus: Mediation by Maternal Metabolites
Aims: To examine the association between non‐traditional lipid parameters and adverse pregnancy outcomes (APOs) in women with gestational diabetes mellitus (GDM) and the mediating role of maternal serum metabolites during pregnancy.Materials and Methods: This prospective observational study enrolled 399 women with GDM. Multivariate logistic regression was used to examine the association between non‐traditional lipid parameters and APOs risk. Additionally, we assessed the mediating role of single and composite maternal serum metabolites during pregnancy using causal mediation analysis and high‐dimensional mediation analysis, respectively.Results: APOs were observed in 12.0% (N = 48) of participants. Seven non‐traditional lipid parameters, except for the RC/HDL‐C ratio, were associated with APOs risk, with the highest estimate for the atherogenic index of plasma (AIP) (OR = 3.873, 95% CI: 1.079–13.934, p = 0.037) after adjusting for confounders. Maternal metabolic markers mediated these associations, with mediation effect proportions of 21.9%–39.4%. Seven key metabolic markers were identified as potential mediators primarily involved in the biosynthesis of the unsaturated fatty acids pathway. Gene set variation analysis revealed significant differences in the positive regulation of this pathway between the APO and normal pregnancy outcome groups (p = 0.015).Conclusions: Non‐traditional lipid parameters were positively associated with APOs risk in women with GDM. Maternal serum metabolites, predominantly involved in the biosynthesis of unsaturated fatty acids, contribute to these associations.
- Open Access
- 9 May 2025
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 24 (1) , 1-16
Metabolic pathways mediating insulin resistance and gestational diabetes mellitus discovered by high-dimensional systematic Mendelian randomization
Gestational diabetes mellitus (GDM), characterized by insulin resistance (IR) and β-cell dysfunction, is one of the most common complications of pregnancy with unmet needs of prevention methods. To investigate the causal role of insulin resistance and metabolic pathways in the pathogenesis of GDM with our proposed high-dimensional systematic Mendelian randomization (hdsMR) framework. Cases with GDM and controls with normal glucose tolerance were recruited at the University of Hong Kong–Shenzhen Hospital from 2015 to 2018. A total of 566 participants (aged > 18 years), including 274 with GDM, were enrolled after excluding subjects with major chronic diseases or long-term use of medications affecting glycolipid metabolism. Clinical characteristics and serum samples were collected during the GDM screening stage, and the genome and metabolome were tested. A novel hdsMR framework was proposed to estimate the causal role of IR index (Homeostasis Model Assessment of Insulin Resistance, HOMA-IR) and metabolic pathways in the pathogenesis of GDM. Our hdsMR method confirmed that HOMA-IR was causal to GDM (odds ratio, 1.17; 95% confidence interval, 1.04–1.32) and revealed that two metabolic pathways (glyoxylate and dicarboxylate metabolism pathway and lysine degradation pathway) mediated 14.6% and 8.4%, respectively, between HOMA-IR and GDM. In an independent validation cohort comprising 255 pre-diabetic individuals, we showed that both pathways could be intervened through diet (P < 0.05). Furthermore, glyoxylate and dicarboxylate metabolism pathway was significantly associated with adverse pregnancy outcomes in GDM. These results indicated that targeting specific metabolic pathways through dietary intervention is worth exploring as a possible GDM prevention approach, and hdsMR is more efficient in finding causal mediating metabolic pathways than traditional MR methods.
- 9 May 2025
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 24 (1) , 1-16
Open AccessMetabolic pathways mediating insulin resistance and gestational diabetes mellitus discovered by high-dimensional systematic Mendelian randomization
Gestational diabetes mellitus (GDM), characterized by insulin resistance (IR) and β-cell dysfunction, is one of the most common complications of pregnancy with unmet needs of prevention methods. To investigate the causal role of insulin resistance and metabolic pathways in the pathogenesis of GDM with our proposed high-dimensional systematic Mendelian randomization (hdsMR) framework. Cases with GDM and controls with normal glucose tolerance were recruited at the University of Hong Kong–Shenzhen Hospital from 2015 to 2018. A total of 566 participants (aged > 18 years), including 274 with GDM, were enrolled after excluding subjects with major chronic diseases or long-term use of medications affecting glycolipid metabolism. Clinical characteristics and serum samples were collected during the GDM screening stage, and the genome and metabolome were tested. A novel hdsMR framework was proposed to estimate the causal role of IR index (Homeostasis Model Assessment of Insulin Resistance, HOMA-IR) and metabolic pathways in the pathogenesis of GDM. Our hdsMR method confirmed that HOMA-IR was causal to GDM (odds ratio, 1.17; 95% confidence interval, 1.04–1.32) and revealed that two metabolic pathways (glyoxylate and dicarboxylate metabolism pathway and lysine degradation pathway) mediated 14.6% and 8.4%, respectively, between HOMA-IR and GDM. In an independent validation cohort comprising 255 pre-diabetic individuals, we showed that both pathways could be intervened through diet (P < 0.05). Furthermore, glyoxylate and dicarboxylate metabolism pathway was significantly associated with adverse pregnancy outcomes in GDM. These results indicated that targeting specific metabolic pathways through dietary intervention is worth exploring as a possible GDM prevention approach, and hdsMR is more efficient in finding causal mediating metabolic pathways than traditional MR methods.
- Open Access
- 28 February 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 110 (11) , e3783-e3793
Reference Intervals for 24-Hour Urinary Calcium Excretion and Its Association With Bone Metabolism: A Multicenter Study
Context: The 24-hour urinary calcium excretion (UCaE) not only serves as an important indicator of calcium metabolism balance but also correlates with metabolic diseases. However, the distribution of 24-hour UCaE and its relationship with bone metabolism are unknown. Objective: To investigate the distribution of 24-hour UCaE and its association with bone metabolism. Methods: In this multicenter cross-sectional study, 1239 participants underwent physical examinations at 9 tertiary hospitals. Multivariate linear regression was used to explore bone metabolism associated with 24-hour UCaE. The relationship of bone metabolism with 24-hour urinary calcium excretion/urinary creatinine (UCaE/Ucr) was analyzed by using restrictive cubic splines fitting multiple linear regression model. Results: The 24-hour UCaE median range was 2.27 mmol overall, 2.24 mmol in men, and 2.28 mmol in women. For men, the highest 24-hour UCaE/Ucr was observed in those aged between 30 and 44 years (median: 0.70), whereas the lowest was found aged between 18 and 29 years (median: 0.46). For women, the 24-hour UCaE/Ucr showed a gradual increase with advancing age. In the adjusted model, 24-hour UCaE/Ucr was independently positively associated with 25(OH)D in both men (P = .032) and women (P < .001). It was independently associated with parathyroid hormone (PTH) (P = .031), type Ⅰ collagen-containing cross-linked C-telopeptide (β-CTX) (P = .021) and procollagen type I N-propeptide (P1NP) (P = .048) in men, but not in women. The prevalence of hypercalciuria was 11.6% (men 7.5%; women 14.0%) and significantly varied across age groups and regions (P < .05). Conclusion: This study established reference intervals for 24-hour UCaE in the Chinese population. This study found gender differences in the relationship between 24-hour UCaE and bone metabolism.
- 28 February 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 110 (11) , e3783-e3793
Open AccessReference Intervals for 24-Hour Urinary Calcium Excretion and Its Association With Bone Metabolism: A Multicenter Study
Context: The 24-hour urinary calcium excretion (UCaE) not only serves as an important indicator of calcium metabolism balance but also correlates with metabolic diseases. However, the distribution of 24-hour UCaE and its relationship with bone metabolism are unknown. Objective: To investigate the distribution of 24-hour UCaE and its association with bone metabolism. Methods: In this multicenter cross-sectional study, 1239 participants underwent physical examinations at 9 tertiary hospitals. Multivariate linear regression was used to explore bone metabolism associated with 24-hour UCaE. The relationship of bone metabolism with 24-hour urinary calcium excretion/urinary creatinine (UCaE/Ucr) was analyzed by using restrictive cubic splines fitting multiple linear regression model. Results: The 24-hour UCaE median range was 2.27 mmol overall, 2.24 mmol in men, and 2.28 mmol in women. For men, the highest 24-hour UCaE/Ucr was observed in those aged between 30 and 44 years (median: 0.70), whereas the lowest was found aged between 18 and 29 years (median: 0.46). For women, the 24-hour UCaE/Ucr showed a gradual increase with advancing age. In the adjusted model, 24-hour UCaE/Ucr was independently positively associated with 25(OH)D in both men (P = .032) and women (P < .001). It was independently associated with parathyroid hormone (PTH) (P = .031), type Ⅰ collagen-containing cross-linked C-telopeptide (β-CTX) (P = .021) and procollagen type I N-propeptide (P1NP) (P = .048) in men, but not in women. The prevalence of hypercalciuria was 11.6% (men 7.5%; women 14.0%) and significantly varied across age groups and regions (P < .05). Conclusion: This study established reference intervals for 24-hour UCaE in the Chinese population. This study found gender differences in the relationship between 24-hour UCaE and bone metabolism.
- Open Access
- 13 February 2025
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 15, 1418932
Metabolomics study of osteopetrosis caused by CLCN7 mutation reveals novel pathway and potential biomarkers
Objective: CLCN7 mutation caused abnormal osteoclasts, resulting in osteopetrosis. Depending on the type of mutation, CLCN7 mutations can lead to severe or relatively benign forms of osteopetrosis. However, the serum metabolic alterations in osteopetrosis caused by CLCN7 mutation are still unknown. We aimed to investigate the differences in the metabolome of osteopetrosis patients caused by CLCN7 mutation versus healthy controls (HC), uncovering potential subtype diagnosis biomarkers.Methods: 19 osteopetrosis patients caused by CLCN7 mutation and 19 HC were recruited for liquid chromatography–tandem mass spectrometry analysis. The screened pathway was validated in the myeloid cell specific Clcn7G763R mutant mouse model by quantitative real-time PCR analysis.Results: Three metabolic pathways were significantly enriched, including glycerophospholipid metabolism (P=0.036948), arachidonic acid metabolism (P=0.0058585) and linoleic acid metabolism (P=0.032035). Ten differential expressed metabolites were located in these three pathways and classified ability with areas under the curve over 0.7 in receiver operating characteristic analysis, suggesting a certain accuracy for being the potential biological markers. Especially, we found that the proteins in glycerophospholipid metabolism were predicted to interact with ClC-7 and further verified that the expression of coding genes were significantly up-regulated in myeloid cell specific Clcn7G763R mutant mouse.Conclusion: This study provides data on serum metabolomics in osteopetrosis caused by CLCN7 mutation and provides new potential metabolic markers and pathways for diagnosis and pathogenesis of osteopetrosis.
- 13 February 2025
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 15, 1418932
Open AccessMetabolomics study of osteopetrosis caused by CLCN7 mutation reveals novel pathway and potential biomarkers
Objective: CLCN7 mutation caused abnormal osteoclasts, resulting in osteopetrosis. Depending on the type of mutation, CLCN7 mutations can lead to severe or relatively benign forms of osteopetrosis. However, the serum metabolic alterations in osteopetrosis caused by CLCN7 mutation are still unknown. We aimed to investigate the differences in the metabolome of osteopetrosis patients caused by CLCN7 mutation versus healthy controls (HC), uncovering potential subtype diagnosis biomarkers.Methods: 19 osteopetrosis patients caused by CLCN7 mutation and 19 HC were recruited for liquid chromatography–tandem mass spectrometry analysis. The screened pathway was validated in the myeloid cell specific Clcn7G763R mutant mouse model by quantitative real-time PCR analysis.Results: Three metabolic pathways were significantly enriched, including glycerophospholipid metabolism (P=0.036948), arachidonic acid metabolism (P=0.0058585) and linoleic acid metabolism (P=0.032035). Ten differential expressed metabolites were located in these three pathways and classified ability with areas under the curve over 0.7 in receiver operating characteristic analysis, suggesting a certain accuracy for being the potential biological markers. Especially, we found that the proteins in glycerophospholipid metabolism were predicted to interact with ClC-7 and further verified that the expression of coding genes were significantly up-regulated in myeloid cell specific Clcn7G763R mutant mouse.Conclusion: This study provides data on serum metabolomics in osteopetrosis caused by CLCN7 mutation and provides new potential metabolic markers and pathways for diagnosis and pathogenesis of osteopetrosis.
- Open Access
- 20 January 2025
- Published by MDPI AG in Metabolites
- Vol. 15 (1) , 66
Osteopenia Metabolomic Biomarkers for Early Warning of Osteoporosis
Introduction: This study aimed to capture the early metabolic changes before osteoporosis occurs and identify metabolomic biomarkers at the osteopenia stage for the early prevention of osteoporosis. Materials and Methods: Metabolomic data were generated from normal, osteopenia, and osteoporosis groups with 320 participants recruited from the Nicheng community in Shanghai. We conducted individual edge network analysis (iENA) combined with a random forest to detect metabolomic biomarkers for the early warning of osteoporosis. Weighted Gene Co-Expression Network Analysis (WGCNA) and mediation analysis were used to explore the clinical impacts of metabolomic biomarkers. Results: Visual separations of the metabolic profiles were observed between three bone mineral density (BMD) groups in both genders. According to the iENA approach, several metabolites had significant abundance and association changes in osteopenia participants, confirming that osteopenia is a critical stage in the development of osteoporosis. Metabolites were further selected to identify osteopenia (nine metabolites in females; eight metabolites in males), and their ability to discriminate osteopenia was improved significantly compared to traditional bone turnover markers (BTMs) (female AUC = 0.717, 95% CI 0.547–0.882, versus BTMs: p = 0.036; male AUC = 0.801, 95% CI 0.636–0.966, versus BTMs: p = 0.007). The roles of the identified key metabolites were involved in the association between total fat-free mass (TFFM) and osteopenia in females. Conclusion: Osteopenia was identified as a tipping point during the development of osteoporosis with metabolomic characteristics. A few metabolites were identified as candidate early-warning biomarkers by machine learning analysis, which could indicate bone loss and provide new prevention guidance for osteoporosis.
- 20 January 2025
- Published by MDPI AG in Metabolites
- Vol. 15 (1) , 66
Open AccessOsteopenia Metabolomic Biomarkers for Early Warning of Osteoporosis
Introduction: This study aimed to capture the early metabolic changes before osteoporosis occurs and identify metabolomic biomarkers at the osteopenia stage for the early prevention of osteoporosis. Materials and Methods: Metabolomic data were generated from normal, osteopenia, and osteoporosis groups with 320 participants recruited from the Nicheng community in Shanghai. We conducted individual edge network analysis (iENA) combined with a random forest to detect metabolomic biomarkers for the early warning of osteoporosis. Weighted Gene Co-Expression Network Analysis (WGCNA) and mediation analysis were used to explore the clinical impacts of metabolomic biomarkers. Results: Visual separations of the metabolic profiles were observed between three bone mineral density (BMD) groups in both genders. According to the iENA approach, several metabolites had significant abundance and association changes in osteopenia participants, confirming that osteopenia is a critical stage in the development of osteoporosis. Metabolites were further selected to identify osteopenia (nine metabolites in females; eight metabolites in males), and their ability to discriminate osteopenia was improved significantly compared to traditional bone turnover markers (BTMs) (female AUC = 0.717, 95% CI 0.547–0.882, versus BTMs: p = 0.036; male AUC = 0.801, 95% CI 0.636–0.966, versus BTMs: p = 0.007). The roles of the identified key metabolites were involved in the association between total fat-free mass (TFFM) and osteopenia in females. Conclusion: Osteopenia was identified as a tipping point during the development of osteoporosis with metabolomic characteristics. A few metabolites were identified as candidate early-warning biomarkers by machine learning analysis, which could indicate bone loss and provide new prevention guidance for osteoporosis.
- Open Access
- 25 April 2023
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 14
Identifying therapeutic biomarkers of zoledronic acid by metabolomics
Zoledronic acid (ZOL) is a potent antiresorptive agent that increases bone mineral density (BMD) and reduces fracture risk in postmenopausal osteoporosis (PMOP). The anti-osteoporotic effect of ZOL is determined by annual BMD measurement. In most cases, bone turnover markers function as early indicators of therapeutic response, but they fail to reflect long-term effects. We used untargeted metabolomics to characterize time-dependent metabolic shifts in response to ZOL and to screen potential therapeutic markers. In addition, bone marrow RNA-seq was performed to support plasma metabolic profiling. Sixty rats were assigned to sham-operated group (SHAM, n = 21) and ovariectomy group (OVX, n = 39) and received sham operation or bilateral ovariectomy, respectively. After modeling and verification, rats in the OVX group were further divided into normal saline group (NS, n = 15) and ZOL group (ZA, n = 18). Three doses of 100 μg/kg ZOL were administrated to the ZA group every 2 weeks to simulate 3-year ZOL therapy in PMOP. An equal volume of saline was administered to the SHAM and NS groups. Plasma samples were collected at five time points for metabolic profiling. At the end of the study, selected rats were euthanatized for bone marrow RNA-seq. A total number of 163 compound were identified as differential metabolites between the ZA and NS groups, including mevalonate, a critical molecule in target pathway of ZOL. In addition, prolyl hydroxyproline (PHP), leucyl hydroxyproline (LHP), 4-vinylphenol sulfate (4-VPS) were identified as differential metabolites throughout the study. Moreover, 4-VPS negatively correlated with increased vertebral BMD after ZOL administration as time-series analysis revealed. Bone marrow RNA-seq showed that the PI3K-AKT signaling pathway was significantly associated with ZOL-mediated changes in expression (adjusted-p = 0.018). In conclusion, mevalonate, PHP, LHP, and 4-VPS are candidate therapeutic markers of ZOL. The pharmacological effect of ZOL likely occurs through inhibition of the PI3K-AKT signaling pathway.
- 25 April 2023
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 14
Open AccessIdentifying therapeutic biomarkers of zoledronic acid by metabolomics
Zoledronic acid (ZOL) is a potent antiresorptive agent that increases bone mineral density (BMD) and reduces fracture risk in postmenopausal osteoporosis (PMOP). The anti-osteoporotic effect of ZOL is determined by annual BMD measurement. In most cases, bone turnover markers function as early indicators of therapeutic response, but they fail to reflect long-term effects. We used untargeted metabolomics to characterize time-dependent metabolic shifts in response to ZOL and to screen potential therapeutic markers. In addition, bone marrow RNA-seq was performed to support plasma metabolic profiling. Sixty rats were assigned to sham-operated group (SHAM, n = 21) and ovariectomy group (OVX, n = 39) and received sham operation or bilateral ovariectomy, respectively. After modeling and verification, rats in the OVX group were further divided into normal saline group (NS, n = 15) and ZOL group (ZA, n = 18). Three doses of 100 μg/kg ZOL were administrated to the ZA group every 2 weeks to simulate 3-year ZOL therapy in PMOP. An equal volume of saline was administered to the SHAM and NS groups. Plasma samples were collected at five time points for metabolic profiling. At the end of the study, selected rats were euthanatized for bone marrow RNA-seq. A total number of 163 compound were identified as differential metabolites between the ZA and NS groups, including mevalonate, a critical molecule in target pathway of ZOL. In addition, prolyl hydroxyproline (PHP), leucyl hydroxyproline (LHP), 4-vinylphenol sulfate (4-VPS) were identified as differential metabolites throughout the study. Moreover, 4-VPS negatively correlated with increased vertebral BMD after ZOL administration as time-series analysis revealed. Bone marrow RNA-seq showed that the PI3K-AKT signaling pathway was significantly associated with ZOL-mediated changes in expression (adjusted-p = 0.018). In conclusion, mevalonate, PHP, LHP, and 4-VPS are candidate therapeutic markers of ZOL. The pharmacological effect of ZOL likely occurs through inhibition of the PI3K-AKT signaling pathway.
- Open Access
- 6 January 2023
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 108 (7) , 1768-1775
Genomic Profiling Reveals the Variant Landscape of Sporadic Parathyroid Adenomas in Chinese Population
Objective To define somatic variants of parathyroid adenoma (PA) and to provide novel insights into the underlying molecular mechanism of sporadic PA. Methods Basic clinical characteristics and biochemical indices of 73 patients with PA were collected. Whole-exome sequencing was performed on matched tumor-constitutional DNA pairs to detect somatic alterations. Functional annotation was carried out by ingenuity pathway analysis afterward. The protein expression of the variant gene was confirmed by immunohistochemistry, and the relationship between genotype and phenotype was analyzed. Results Somatic variants were identified in 1549 genes, with an average of 69 variants per tumor (range, 13-2109; total, 9083). Several novel recurrent somatic variants were detected, such as KMT2D (15/73), MUC4 (14/73), POTEH (13/73), CD22 (12/73), HSPA2 (12/73), HCFC1 (11/73), MAGEA1 (11/73), and SLC4A3 (11/73), besides the previously reported PA-related genes, including MEN1 (11/73), CASR (6/73), MTOR (4/73), ASXL3 (3/73), FAT1 (3/73), ZFX (5/73), EZH1 (2/73), POT1 (2/73), and EZH2 (1/73). Among them, KMT2D might be the candidate driver gene of PA. Crucially, 5 patients carried somatic mutations in CDC73, showed an aggressive phenotype similar to that of parathyroid carcinoma (PC), and had a decreased expression of parafibromin. Pathway analysis of recurrent potential PA-associated driver variant genes revealed functional enrichments in the signaling pathway of Notch. Conclusion Our study expanded the pathogenic variant spectrum of PA and indicated that KMT2D might be a novel candidate driver gene and be considered as a diagnostic biomarker for PA. Meanwhile, CDC73 mutations might be an early developmental event from PA to PC. The results provided insights into elucidating the pathogenesis of parathyroid tumorigenesis and a certain basis for clinical diagnosis and treatment.
- 6 January 2023
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 108 (7) , 1768-1775
Open AccessGenomic Profiling Reveals the Variant Landscape of Sporadic Parathyroid Adenomas in Chinese Population
Objective To define somatic variants of parathyroid adenoma (PA) and to provide novel insights into the underlying molecular mechanism of sporadic PA. Methods Basic clinical characteristics and biochemical indices of 73 patients with PA were collected. Whole-exome sequencing was performed on matched tumor-constitutional DNA pairs to detect somatic alterations. Functional annotation was carried out by ingenuity pathway analysis afterward. The protein expression of the variant gene was confirmed by immunohistochemistry, and the relationship between genotype and phenotype was analyzed. Results Somatic variants were identified in 1549 genes, with an average of 69 variants per tumor (range, 13-2109; total, 9083). Several novel recurrent somatic variants were detected, such as KMT2D (15/73), MUC4 (14/73), POTEH (13/73), CD22 (12/73), HSPA2 (12/73), HCFC1 (11/73), MAGEA1 (11/73), and SLC4A3 (11/73), besides the previously reported PA-related genes, including MEN1 (11/73), CASR (6/73), MTOR (4/73), ASXL3 (3/73), FAT1 (3/73), ZFX (5/73), EZH1 (2/73), POT1 (2/73), and EZH2 (1/73). Among them, KMT2D might be the candidate driver gene of PA. Crucially, 5 patients carried somatic mutations in CDC73, showed an aggressive phenotype similar to that of parathyroid carcinoma (PC), and had a decreased expression of parafibromin. Pathway analysis of recurrent potential PA-associated driver variant genes revealed functional enrichments in the signaling pathway of Notch. Conclusion Our study expanded the pathogenic variant spectrum of PA and indicated that KMT2D might be a novel candidate driver gene and be considered as a diagnostic biomarker for PA. Meanwhile, CDC73 mutations might be an early developmental event from PA to PC. The results provided insights into elucidating the pathogenesis of parathyroid tumorigenesis and a certain basis for clinical diagnosis and treatment.